Paul Hudson, MD
Interventional Cardiology · Green Bay, WINPI 1417094772
Payments from drug & device makers
What this record shows
The money is spread across several categories — travel and lodging (43.2%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. 25 manufacturers reported payments, led by Edwards Lifesciences at 53.6% of the total. 2025 is the largest year on record at $10,538, more than ten times the $507 reported in 2019.
Across 112 payments — averaging $214.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Edwards Lifesciences$13K
- Medtronic$9K
- Boston Scientific$927
- Abbott$272
- Abiomed$187
- Silk Road Medical, Inc.$152
- plus $774 from 19 others
Across 2 payments — averaging $2012.50 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Bard Peripheral Vascular, Inc.$4K
What the payments were for
- Consulting fees$9,03038%
- Travel & lodging$10,38943%
- Food & beverage$4,61919%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Edwards Lifesciences | 36 | $12,873 |
| Medtronic(2 entities) | 19 | $8,852 |
| Boston Scientific | 14 | $927 |
| Abbott | 6 | $272 |
| Abiomed | 3 | $187 |
| Silk Road Medical, Inc. | 1 | $152 |
| E.r. Squibb & Sons, L.L.C. | 5 | $135 |
| Novartis | 6 | $126 |
| Cook Medical LLC | 1 | $89 |
| Amgen | 2 | $78 |
| Stryker | 1 | $53 |
| Chiesi USA, Inc. | 2 | $37 |
| United Therapeutics Corporation | 2 | $31 |
| AstraZeneca | 2 | $29 |
| W. L. Gore & Associates, Inc. | 2 | $25 |
| Biosense Webster, Inc. | 1 | $23 |
| Bard Peripheral Vascular, Inc. | 1 | $22 |
| Boehringer Ingelheim | 1 | $19 |
| Surmodics, Inc. | 1 | $19 |
| Teleflex LLC | 1 | $17 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $16 |
| Acist Medical Systems, Inc. | 1 | $14 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $14 |
| Lexicon Pharmaceuticals, Inc. | 1 | $14 |
| Johnson & Johnson | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$24,038 in reported general payments places this provider in the 80th percentile of 118 interventional cardiology providers in Wisconsin.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 263 | $239,145 |
| XareltoRivaroxaban | 40 | $56,381 |
| EntrestoSacubitril/Valsartan | 44 | $32,976 |
| Repatha SureclickEvolocumab | 26 | $28,292 |
| BrilintaTicagrelor | 39 | $24,765 |
| JardianceEmpagliflozin | 19 | $18,594 |
| Praluent PenAlirocumab | 20 | $15,626 |
| Repatha SyringeEvolocumab | 13 | $8,291 |
| Metoprolol Succinate | 334 | $5,382 |
| ClopidogrelClopidogrel Bisulfate | 167 | $2,113 |
| Warfarin Sodium | 203 | $1,724 |
| Potassium Chloride | 100 | $1,713 |
| Furosemide | 203 | $1,340 |
| Atorvastatin Calcium | 156 | $1,244 |
| Bumetanide | 23 | $1,226 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonXarelto | $13 | $56,38140 claims |
| NovartisEntresto | $126 | $32,97644 claims |
| AstraZenecaBrilinta | $29 | $24,76539 claims |
| Boehringer IngelheimJardiance | $19 | $18,59419 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 118 interventional cardiology providers in Wisconsin.
Other interventional cardiology in Green Bay
- Sampoornima SettyGreen Bay$16K
- Sumit RingwalaGreen Bay$8K
- Simil GalaGreen Bay$4K
- Kristopher SelkeGreen Bay$4K
- Michael SalingerMilwaukee$216K
- Arun KalyanasundaramMarshfield$201K
- Michael RosenbergManitowoc$111K
- Tanvir BajwaMilwaukee$106K
- Suhail AllaqabandMilwaukee$88K
- Saif AnwaruddinMilwaukee$80K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.